- Brennan, Patricia A;
- Dunlop, Anne L;
- Croen, Lisa A;
- Avalos, Lyndsay A;
- Salisbury, Amy L;
- Hipwell, Alison E;
- Nozadi, Sara S;
- Sathyanarayana, Sheela;
- Crum, Rosa M;
- Musci, Rashelle;
- Li, Mingyi;
- Li, Xiuhong;
- Mansolf, Maxwell;
- O’Connor, Thomas G;
- Elliott, Amy J;
- Ghildayal, Nidhi;
- Lin, Pi-I D;
- Sprowles, Jenna LN;
- Stanford, Joseph B;
- Bendixsen, Casper;
- Ozonoff, Sally;
- Lester, Barry M;
- Shuster, Coral L;
- Huddleston, Kathi C;
- Posner, Jonathan;
- Paneth, Nigel
Prenatal antidepressant exposure has been associated with increased risk for neurodevelopmental disorders in childhood, including autism spectrum disorder (ASD). The current study utilized multi-cohort data from the Environmental influences on Child Health Outcomes (ECHO) program (N = 3129) to test for this association, and determine whether the association remained after adjusting for maternal prenatal depression and other potential confounders. Antidepressants and a subset of selective serotonin reuptake inhibitors (SSRIs) were examined in relation to binary (e.g., diagnostic) and continuous measures of ASD and ASD related traits (e.g., social difficulties, behavior problems) in children 1.5 to 12 years of age. Child sex was tested as an effect modifier. While prenatal antidepressant exposure was associated with ASD related traits in univariate analyses, these associations were statistically non-significant in models that adjusted for prenatal maternal depression and other maternal and child characteristics. Sex assigned at birth was not an effect modifier for the prenatal antidepressant and child ASD relationship. Overall, we found no association between prenatal antidepressant exposures and ASD diagnoses or traits. Discontinuation of antidepressants in pregnancy does not appear to be warranted on the basis of increased risk for offspring ASD.